{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"1"},{"groupId":"OG008","value":"1"}],"units":"Participants"}],"description":"The number of patients achieving complete response during treatment on study","groups":[{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG000","title":"Vincristine Sulfate Liposome Injection 1.8 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG001","title":"Vincristine Sulfate Liposome Injection 1.95 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG002","title":"Vincristine Sulfate Liposome Injection 1.98 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG003","title":"Vincristine Sulfate Liposome Injection 2.04 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG004","title":"Vincristine Sulfate Liposome Injection 2.10 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG005","title":"Vincristine Sulfate Liposome Injection 2.14 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG006","title":"Vincristine Sulfate Liposome Injection 2.19 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG007","title":"Vincristine Sulfate Liposome Injection 2.22 mg/m^2"},{"description":"Treatment with the combination of rituximab, bendamustine and vincristine sulfate liposome injection will be repeated every 4 weeks for a maximum of 6 cycles. Dose-limiting toxicities will be evaluated during the first cycle of therapy.\n\nRituximab: 375 mg/m2 I.V. on Day 1 of each cycle\n\nBendamustine: 90 mg/m2 I.V. on Day 1 and 2 of each cycle\n\nVincristine sulfate liposome injection: Dose per dose escalation protocol, I.V. on Day 2 of each cycle","id":"OG008","title":"Vincristine Sulfate Liposome Injection 2.24 mg/m^2"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 6 cycles of treatment (approximately 6 months)","title":"Complete Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}